TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jan 11, 2023 12:52 JST
Source:
Eisai
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
TOKYO, Jan 11, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) to the European Medicines Agency (EMA). This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study (Study 201), which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD, and is subject to a validation to determine whether the EMA accepts the application for review.
The Clarity AD study met its primary endpoint (CDR-SB(1): Clinical Dementia Rating-Sum of Boxes) and all key secondary endpoints with highly statistically significant results. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.
In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference, and simultaneously published in the New England Journal of Medicine, peer-reviewed medical journals.
In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on the same day. In China, Eisai has initiated submission of data for BLA to the National Medical Products Administration (NMPA) of China in December 2022. In Japan, Eisai plans to submit a marketing authorization application by the end of Eisai's fiscal year 2022, which ends March 31, 2023.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
(1) CDR-SB is a numeric scale used to quantify the various severity of symptoms of dementia. Based on interviews of people living with AD and family/caregivers, qualified healthcare professionals assess cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score of the six areas is the score of CDR-SB, and CDR-SB is also used as an appropriate item for evaluating the effectiveness of therapeutic drugs targeting the early stages of AD.
Media Contacts:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Europe, Ltd.
(Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net
Biogen Inc.
Natacha Gassenbach
+ 1-857-777-6573
public.affairs@biogen.com
Investor Contacts:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Mike Hencke
+ 1-781-464-2442
IR@biogen.com
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
April 30 2025 13:17 JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
April 18 2025 15:52 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
April 01 2025 12:15 JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
March 25 2025 16:28 JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
March 25 2025 11:21 JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
March 10 2025 19:24 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
March 05 2025 08:09 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
March 04 2025 16:22 JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
March 03 2025 14:41 JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
March 03 2025 12:53 JST
More Press release >>
Latest Press Release
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 09, 2025 16:03 JST
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 09, 2025 16:00 JST
Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026
May 08, 2025 11:25 JST
Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV
May 08, 2025 11:08 JST
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
May 07, 2025 19:06 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition
May 03, 2025 03:00 JST
TOYOTA GAZOO Racing Set for Spa spectacle
May 02, 2025 19:29 JST
FWD Group reports exceptionally strong first quarter new business update
May 02, 2025 17:00 JST
Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand
May 01, 2025 17:48 JST
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 30, 2025 17:20 JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 30, 2025 14:17 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Apr 25, 2025 17:50 JST
Olympus Appoints New CEO
Apr 25, 2025 15:30 JST
DENSO Announces Year-End Financial Results
Apr 25, 2025 12:17 JST
DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture
Apr 24, 2025 18:43 JST
MyJCB App Wins "iF DESIGN AWARD 2025"
Apr 24, 2025 17:00 JST
Fujitsu launches new company 1FINITY to strengthen network products business
Apr 24, 2025 16:24 JST
MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture
Apr 24, 2025 15:01 JST
More Latest Release >>